{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:10:38Z","timestamp":1787062238849,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Frances Brody Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Changing practice guidelines and recommendations have important implications for cancer survivors. This study investigated genetic testing patterns and outcomes and reported family history of pancreatic cancer (FHPC) in a large registry population of breast cancer (BC) patients. Variables including clinical and demographic characteristics, FHPC in a first or second-degree relative, and genetic testing outcomes were analyzed for BC patients diagnosed between 2010 and 2018 in the NYU Langone Health Breast Cancer Database. Among 3334 BC patients, 232 (7%) had a positive FHPC. BC patients with FHPC were 1.68 times more likely to have undergone genetic testing (p\u2009&lt;\u20090.001), but 33% had testing for\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    only and 44% had no genetic testing. Pathogenic germline variants (PGV) were identified in 15\/129 (11.6%) BC patients with FHPC, and in 145\/1315 (11.0%) BC patients without FHPC. Across both groups, updates in genetic testing criteria and recommendations could impact up to 80% of this cohort. Within a contemporary cohort of BC patients, 7% had a positive FHPC. The majority of these patients (56%) had no genetic testing, or incomplete testing by current standards, suggesting under-diagnosis of PC risk. This study supports recommendations for survivorship care that incorporate ongoing genetic risk assessment and counseling.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-91971-0","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T06:02:37Z","timestamp":1623650557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Annie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N.","family":"Everett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"91971_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","volume":"34","author":"CD Runowicz","year":"2016","unstructured":"Runowicz, C. D. et al. American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J. Clin. Oncol. 34, 611\u2013635. https:\/\/doi.org\/10.1200\/JCO.2015.64.3809 (2016).","journal-title":"J. Clin. Oncol."},{"key":"91971_CR2","unstructured":"Cancer Facts and Figures 2020. (American Cancer Society, Atlanta, 2020). https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2020\/cancer-facts-and-figures-2020.pdf. Accessed 1 April 2021.\u00a0"},{"key":"91971_CR3","first-page":"8","volume":"46","author":"O Ishikawa","year":"1999","unstructured":"Ishikawa, O. et al. Minute carcinoma of the pancreas measuring 1\u00a0cm or less in diameter\u2013collective review of Japanese case reports. Hepatogastroenterology 46, 8\u201315 (1999).","journal-title":"Hepatogastroenterology"},{"key":"91971_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jama.2019.10232","volume":"322","author":"US Preventive Services Task Force","year":"2019","unstructured":"US Preventive Services Task Force et al. Screening for pancreatic cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 322, 438\u2013444. https:\/\/doi.org\/10.1001\/jama.2019.10232 (2019).","journal-title":"JAMA"},{"key":"91971_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","volume":"69","author":"M Goggins","year":"2020","unstructured":"Goggins, M. et al. Management of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69, 7\u201317. https:\/\/doi.org\/10.1136\/gutjnl-2019-319352 (2020).","journal-title":"Gut"},{"key":"91971_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ajg.2014.435","volume":"110","author":"S Syngal","year":"2015","unstructured":"Syngal, S. et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am. J. Gastroenterol. 110, 223\u2013262. https:\/\/doi.org\/10.1038\/ajg.2014.435 (2015) (quiz 263, Epub 2015 Feb 3).","journal-title":"Am. J. Gastroenterol."},{"key":"91971_CR7","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/JCO.2015.64.0730","volume":"34","author":"H Vasen","year":"2016","unstructured":"Vasen, H. et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European Expert Centers. J. Clin. Oncol. 34, 2010\u20132019. https:\/\/doi.org\/10.1200\/JCO.2015.64.0730 (2016) (Epub 2016 Apr 25).","journal-title":"J. Clin. Oncol."},{"key":"91971_CR8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.05.035","author":"MI Canto","year":"2018","unstructured":"Canto, M. I. et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2018.05.035 (2018).","journal-title":"Gastroenterology"},{"key":"91971_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-019-04230-z","author":"MI Canto","year":"2019","unstructured":"Canto, M. I. et al. Surgical outcomes after pancreatic resection of screening-detected lesions in individuals at high risk for developing pancreatic cancer. J Gastrointest. Surg. https:\/\/doi.org\/10.1007\/s11605-019-04230-z (2019).","journal-title":"J Gastrointest. Surg."},{"key":"91971_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/1055-9965.Epi-12-0195","volume":"22","author":"E Mocci","year":"2013","unstructured":"Mocci, E. et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol. Biomark. Prevent. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prevent. Oncol. 22, 803\u2013811. https:\/\/doi.org\/10.1158\/1055-9965.Epi-12-0195 (2013).","journal-title":"Cancer Epidemiol. Biomark. Prevent. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prevent. Oncol."},{"key":"91971_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31628","author":"R Brand","year":"2018","unstructured":"Brand, R. et al. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer https:\/\/doi.org\/10.1002\/cncr.31628 (2018).","journal-title":"Cancer"},{"key":"91971_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0009-5","author":"MB Yurgelun","year":"2018","unstructured":"Yurgelun, M. B. et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet. Med. https:\/\/doi.org\/10.1038\/s41436-018-0009-5 (2018).","journal-title":"Genet. Med."},{"key":"91971_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3502","author":"K Shindo","year":"2017","unstructured":"Shindo, K. et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.72.3502 (2017).","journal-title":"J. Clin. Oncol."},{"key":"91971_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","volume":"148","author":"RC Grant","year":"2015","unstructured":"Grant, R. C. et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148, 556\u2013564. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.042 (2015) (Epub 2014 Dec 2).","journal-title":"Gastroenterology"},{"key":"91971_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1158\/1055-9965.EPI-15-0455","volume":"25","author":"C Hu","year":"2016","unstructured":"Hu, C. et al. Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. Cancer Epidemiol. Biomark. Prev. 25, 207\u2013211. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0455 (2016) (Epub 2015 Oct 19).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"91971_CR16","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu, C. et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA 319, 2401\u20132409. https:\/\/doi.org\/10.1001\/jama.2018.6228 (2018).","journal-title":"JAMA"},{"key":"91971_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/ng1837","volume":"38","author":"A Renwick","year":"2006","unstructured":"Renwick, A. et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38, 873\u2013875. https:\/\/doi.org\/10.1038\/ng1837 (2006).","journal-title":"Nat. Genet."},{"key":"91971_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/jmedgenet-2015-103216","volume":"52","author":"EF Harkness","year":"2015","unstructured":"Harkness, E. F. et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: A cohort study. J. Med. Genet. 52, 553\u2013556. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103216 (2015).","journal-title":"J. Med. Genet."},{"key":"91971_CR19","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai, P. L. et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122, 3673\u20133681. https:\/\/doi.org\/10.1002\/cncr.30248 (2016).","journal-title":"Cancer"},{"key":"91971_CR20","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402\u20132416. https:\/\/doi.org\/10.1001\/jama.2017.7112 (2017).","journal-title":"JAMA"},{"key":"91971_CR21","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-06-0083","volume":"12","author":"N Hearle","year":"2006","unstructured":"Hearle, N. et al. Frequency and spectrum of cancers in the Peutz\u2013Jeghers syndrome. Clin. Cancer Res. 12, 3209\u20133215. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0083 (2006).","journal-title":"Clin. Cancer Res."},{"key":"91971_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/science.1171202","volume":"324","author":"S Jones","year":"2009","unstructured":"Jones, S. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217. https:\/\/doi.org\/10.1126\/science.1171202 (2009) (Epub 2009 Mar 5).","journal-title":"Science"},{"key":"91971_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382.","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou, A. C. et al. Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med. 371, 497\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1400382. (2014).","journal-title":"N. Engl. J. Med."},{"key":"91971_CR24","unstructured":"NCCN. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf (2020). Accessed 1 April 2021."},{"key":"91971_CR25","doi-asserted-by":"publisher","first-page":"108813","DOI":"10.1016\/j.ejrad.2020.108813","volume":"124","author":"E Mema","year":"2020","unstructured":"Mema, E. et al. The relationship of breast density in mammography and magnetic resonance imaging in women with triple negative breast cancer. Eur. J. Radiol. 124, 108813. https:\/\/doi.org\/10.1016\/j.ejrad.2020.108813 (2020).","journal-title":"Eur. J. Radiol."},{"key":"91971_CR26","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian, A. W. et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J. Clin. Oncol. 37, 1305\u20131315. https:\/\/doi.org\/10.1200\/JCO.18.01854 (2019).","journal-title":"J. Clin. Oncol."},{"key":"91971_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/08998280.2019.1612702","volume":"32","author":"A Swink","year":"2019","unstructured":"Swink, A. et al. Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers. Proc. (Baylor Univ. Med. Cent.) 32, 340\u2013344. https:\/\/doi.org\/10.1080\/08998280.2019.1612702 (2019).","journal-title":"Proc. (Baylor Univ. Med. Cent.)"},{"key":"91971_CR28","doi-asserted-by":"publisher","first-page":"298745","DOI":"10.1155\/2012\/298745","volume":"2012","author":"B Anderson","year":"2012","unstructured":"Anderson, B. et al. Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol 2012, 298745. https:\/\/doi.org\/10.1155\/2012\/298745 (2012).","journal-title":"J Cancer Epidemiol"},{"key":"91971_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10897-016-0064-5","volume":"26","author":"S Hayden","year":"2017","unstructured":"Hayden, S. et al. Large, prospective analysis of the reasons patients do not pursue BRCA genetic testing following genetic counseling. J. Genet. Couns. 26, 859\u2013865. https:\/\/doi.org\/10.1007\/s10897-016-0064-5 (2017).","journal-title":"J. Genet. Couns."},{"key":"91971_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.pec.2017.12.011","volume":"101","author":"J Shaw","year":"2018","unstructured":"Shaw, J. et al. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome. Patient Educ. Couns. 101, 938\u2013944. https:\/\/doi.org\/10.1016\/j.pec.2017.12.011 (2018).","journal-title":"Patient Educ. Couns."},{"key":"91971_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch, P. D. et al. Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle?. J. Clin. Oncol. 37, 453\u2013460. https:\/\/doi.org\/10.1200\/JCO.18.01631 (2019).","journal-title":"J. Clin. Oncol."},{"key":"91971_CR32","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-018-6621-4","volume":"25","author":"S Yang","year":"2018","unstructured":"Yang, S. et al. Underdiagnosis of hereditary breast and ovarian cancer in medicare patients: Genetic testing criteria miss the mark. Ann. Surg. Oncol. 25, 2925\u20132931. https:\/\/doi.org\/10.1245\/s10434-018-6621-4 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"91971_CR33","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1200\/JCO.19.02190","volume":"38","author":"S Yadav","year":"2020","unstructured":"Yadav, S. et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J. Clin. Oncol. 38, 1409\u20131418. https:\/\/doi.org\/10.1200\/JCO.19.02190 (2020).","journal-title":"J. Clin. Oncol."},{"key":"91971_CR34","doi-asserted-by":"crossref","unstructured":"Manahan E.R., S. M., Hughes K.S., Boughey J.C., Kuerer H.M., Euhus D.M., Robson M.E., Boolbol S.K., Arun B.K., Taylor W.A. The American Society of Breast Surgeons consensus guidelines on genetic testing for hereditary breast cancer. https:\/\/www.breastsurgeons.org\/docs\/statements\/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf (2019).","DOI":"10.1245\/s10434-019-07549-8"},{"key":"91971_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jamaoncol.2015.28","volume":"1","author":"AW Kurian","year":"2015","unstructured":"Kurian, A. W. & Ford, J. M. Multigene panel testing in oncology practice: How should we respond?. JAMA Oncol. 1, 277\u2013278. https:\/\/doi.org\/10.1001\/jamaoncol.2015.28 (2015).","journal-title":"JAMA Oncol."},{"key":"91971_CR36","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1200\/JCO.2013.49.7388","volume":"31","author":"K Offit","year":"2013","unstructured":"Offit, K. et al. Gene patents and personalized cancer care: Impact of the Myriad case on clinical oncology. J. Clin. Oncol. 31, 2743\u20132748. https:\/\/doi.org\/10.1200\/JCO.2013.49.7388 (2013).","journal-title":"J. Clin. Oncol."},{"key":"91971_CR37","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","volume":"4","author":"AW Kurian","year":"2018","unstructured":"Kurian, A. W. et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. 4, 1066\u20131072. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0644 (2018).","journal-title":"JAMA Oncol."},{"key":"91971_CR38","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1200\/EDBK_160391","volume":"35","author":"F Lynce","year":"2016","unstructured":"Lynce, F. & Isaacs, C. How far do we go with genetic evaluation? Gene, panel, and tumor testing. Am. Society Clin. Oncol. Educ. Book\/ASCO Am. Society Clin. Oncol. Meeting. 35, e72\u2013e78. https:\/\/doi.org\/10.1200\/EDBK_160391 (2016).","journal-title":"Am. Society Clin. Oncol. Educ. Book\/ASCO Am. Society Clin. Oncol. Meeting."},{"key":"91971_CR39","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","volume":"31","author":"SM Domchek","year":"2013","unstructured":"Domchek, S. M., Bradbury, A., Garber, J. E., Offit, K. & Robson, M. E. Multiplex genetic testing for cancer susceptibility: Out on the high wire without a net?. J. Clin. Oncol. 31, 1267\u20131270. https:\/\/doi.org\/10.1200\/JCO.2012.46.9403 (2013).","journal-title":"J. Clin. Oncol."},{"key":"91971_CR40","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.2013.1468","volume":"309","author":"RV Tuckson","year":"2013","unstructured":"Tuckson, R. V., Newcomer, L. & De Sa, J. M. Accessing genomic medicine: Affordability, diffusion, and disparities. JAMA 309, 1469\u20131470. https:\/\/doi.org\/10.1001\/jama.2013.1468 (2013).","journal-title":"JAMA"},{"key":"91971_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jval.2017.01.006","volume":"20","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value Health 20, 547\u2013555. https:\/\/doi.org\/10.1016\/j.jval.2017.01.006 (2017).","journal-title":"Value Health"},{"key":"91971_CR42","doi-asserted-by":"publisher","first-page":"238146831882110","DOI":"10.1177\/2381468318821103","volume":"4","author":"L Asphaug","year":"2019","unstructured":"Asphaug, L. & Melberg, H. O. The cost-effectiveness of multigene panel testing for hereditary breast and ovarian cancer in Norway. MDM Policy Pract. 4, 2381468318821103. https:\/\/doi.org\/10.1177\/2381468318821103 (2019).","journal-title":"MDM Policy Pract."},{"key":"91971_CR43","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","volume":"32","author":"AW Kurian","year":"2014","unstructured":"Kurian, A. W. et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J. Clin. Oncol. 32, 2001\u20132009. https:\/\/doi.org\/10.1200\/JCO.2013.53.6607 (2014) (Epub 2014 Apr 14).","journal-title":"J. Clin. Oncol."},{"key":"91971_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung, N. et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121, 25\u201333. https:\/\/doi.org\/10.1002\/cncr.29010 (2015).","journal-title":"Cancer"},{"key":"91971_CR45","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10689-016-9956-7","volume":"16","author":"S Yadav","year":"2017","unstructured":"Yadav, S., Reeves, A., Campian, S., Paine, A. & Zakalik, D. Outcomes of retesting BRCA negative patients using multigene panels. Fam. Cancer 16, 319\u2013328. https:\/\/doi.org\/10.1007\/s10689-016-9956-7 (2017).","journal-title":"Fam. Cancer"},{"key":"91971_CR46","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1245\/s10434-017-5963-7","volume":"24","author":"E O'Leary","year":"2017","unstructured":"O\u2019Leary, E. et al. Expanded gene panel use for women with breast cancer: Identification and intervention beyond breast cancer risk. Ann. Surg. Oncol. 24, 3060\u20133066. https:\/\/doi.org\/10.1245\/s10434-017-5963-7 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"91971_CR47","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/jgc4.1173","volume":"28","author":"L Sawyer","year":"2019","unstructured":"Sawyer, L., Creswick, H., Lewandowski, R. & Quillin, J. Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights. J. Genet. Couns. 28, 1198\u20131207. https:\/\/doi.org\/10.1002\/jgc4.1173 (2019).","journal-title":"J. Genet. Couns."},{"key":"91971_CR48","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10897-009-9254-8","volume":"18","author":"H Hampel","year":"2009","unstructured":"Hampel, H. Recontacting patients who have tested negative for BRCA1 and BRCA2 mutations: How, who and why?. J. Genet. Couns. 18, 527\u2013529. https:\/\/doi.org\/10.1007\/s10897-009-9254-8 (2009).","journal-title":"J. Genet. Couns."},{"key":"91971_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/pbc.23283","volume":"58","author":"S Knapke","year":"2012","unstructured":"Knapke, S., Nagarajan, R., Correll, J., Kent, D. & Burns, K. Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr. Blood. 58, 85\u201389. https:\/\/doi.org\/10.1002\/pbc.23283 (2012) (Epub 2011 Aug 17).","journal-title":"Pediatr. Blood."},{"key":"91971_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/JCO.2015.63.5375","volume":"34","author":"KJ Ruddy","year":"2016","unstructured":"Ruddy, K. J., Risendal, B. C., Garber, J. E. & Partridge, A. H. Cancer survivorship care: An opportunity to revisit cancer genetics. J. Clin. Oncol. 34, 539\u2013541. https:\/\/doi.org\/10.1200\/JCO.2015.63.5375 (2016).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91971-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:42:10Z","timestamp":1670042530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91971-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91971"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91971-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"5 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12491"}}